Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis

Statistical Methods in Medical Research

Volumn 14, Issue 4, 2005, Pages 349-367

  Baker, Stuart G ^a   Kramer, Barnett S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT;

ANALYTICAL ERROR; CESAREAN SECTION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA ANALYSIS; HUMAN; LINEAR SYSTEM; MATHEMATICAL COMPUTING; MAXIMUM LIKELIHOOD METHOD; METHODOLOGY; OUTCOMES RESEARCH; POISSON DISTRIBUTION; PROBABILITY; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL;

LIKELIHOOD FUNCTIONS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24944547558     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280205sm404oa     Document Type: Review

References (47)

1. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of Educational Psychology 1974; 66: 688-701.
2. Baker SG. Compliance, all-or-none. In: Kotz S, Read CR, Banks, DL eds. The encyclopedia of statistical science, Update Volume 1. New York: John Wiley and Sons, Inc., 1997; 134-38.
3. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clinical Pharmacology and Therapeutics 1995; 57: 6-15.
4. Baker SG, Lindeman KL. Rethinking historical controls. Biostatistics 2001; 2: 383-96.
5. Baker SG, Lindeman KL. The paired availability design: A proposal for evaluating epidural analgesia during labor. Statistics in Medicine 1994; 13: 2269-78; correction Statistics in Medicine 1995; 14: 1841.
6. Baker SG, Lindeman KL, Kramer BS. The paired availability design for historical controls. BMC Medical Research Methodology 2001; 1: 9.
7. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. Journal of the American Statistical Association 1996; 92: 444-55.
8. Frangakis CE, Rubin DB. Principle stratification in causal inference. Biometrics 2002; 58: 21-29.
9. Rubin DB. Bayesian-inference for causal effects - role of randomization. Annals of Statistics 1978; 6: 34-58.
10. Bloom HS. Accounting for no-shows in experimental evaluation designs. Evaluation Review 1984; 8: 225-46.
11. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Statistics in Medicine 1991; 10: 45-52.
12. Connor R, Prorok PC, Weed DL. The case-control design and the assessment of the efficacy of cancer screening. Journal of Clinical Epidemiology 1991; 44: 1215-21.
13. Newcombe RG. Explanatory and pragmatic estimate of the treatment effect when deviations from allocated treatment occur. Statistics in Medicine 1988; 7: 1179-86.
14. Ihm P. Ein lineares Modell für die Randomisierungspläne von Zelen. In: Victor N, Dudeck J, Broszio EP eds. Medizinische Infomatik und Statistik, vol. 33, Therapiestudien. Berlin: Springer, 1981; 176-88.
15. Sato T. Randomized intent-to-treat analyses. Japanese Journal of Applied Statistics 1994; 23: 21-34 (in Japanese).
16. Permutt T, Hebel J. Simultaneous-equation estimation in a clinical trial of the effect of smoking on birth weight. Biometrics 1989; 45: 619-22.
17. Robins JM. The analysis of randomized and nonrandomized AIDS treatment trials using a new approach to causal inference in longitudinal studies. In: Sechrest L, Freeman H, Mulley A eds, Health service research methodology: a focus on AIDS. Washington, DC: US Public Health Service, 1989: 113-59.
18. Goetghebeur E, Molenberghs G. Causal inference in a placebo-controlled clinical trial with binary outcome and ordered compliance. Journal of the American Statistical Association 1996; 91: 928-34.
19. Baker SG. The paired availability design: An update. In: Abel U, Koch A eds. Nonrandomized comparative clinical studies. Dusseldorf: Symposion Publishing, 1998; 79-84.
20. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Statistics in Medicine 1997; 16: 1017-29.
21. Sato T. Sample size calculations with compliance information. Statistics in Medicine 2000; 19: 2689-97.
22. Imbens G, Rubin DB. Bayesian inference for causal effects in randomized experiments with non compliance. The Annals of Statistics 1997; 25: 305-27.
23. Robins JM, Greenland S. Adjusting for differential rates of prophylaxis therapy for PCP in high-dose versus low-dose AZT treatment arms in an AIDS randomized trial. Journal of the American Statistical Association 1994; 89: 737-49.
24. Baker SG. The multinomial-Poisson transformation. The Statistician 1994; 43: 495-504.
25. Branson M, Whitehead J. A score test for binary data with patient non-compliance. Statistics in Medicine 2003; 22: 3115-32.
26. Yau L, Little R. Inference for complier-average causal effect from longitudinal data subject to noncompliance and missing data, with application to a job training assessment for the unemployed. Journal of the American Statistical Association 2001; 96: 1232-44.
27. Buonaccorsi JP. Fieller's Theorem. In: Armitage P, Colton T. eds. The encyclopedia of biostatistics, Vol. 2, New York: John Wiley and Sons, Inc., 1998; 1515-16.
28. Baker SG, Freedman LS. A simple method for analyzing data from a randomized trial with a missing binary outcome. BMC Medical Research Methodology 2003; 3: 8.
29. Frangakis CE, Rubin DB. Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes. Biometrika 1999; 86: 365-79.
30. Baker SG. Analysis of survival data from a randomized trial with all-or-none compliance: estimating the cost-effectiveness of a cancer screening program. Journal of the American Statistical Association 1998; 93: 929-34.
31. Baker SG. Analyzing a randomized cancer prevention trial with a missing binary outcome, an auxiliary variable, and all-or-none compliance. Journal of the American Statistical Association 2000; 95: 43-50.
32. Glaziou P. Meta-analysis adjusting for compliance: the example of screening for breast cancer. Journal of Clinical Epidemiology 1992; 45: 1251-56.
33. DerSimonian R, Laird NM. Meta analysis of clinical trials. Controlled Clinical Trials 1986; 7: 177-88.
34. Follman DA, Proschan MA. Inference in random effects meta-analysis. Biometrics 1999; 55: 732-37.
35. Baker SG, Kramer BS. Randomized trials, generalizability, and meta-analysis: Graphical insights for binary outcomes. BMC Medical Research Methodology 2003; 3: 10.
36. Goetghebeur E, Molenberghs G, Katz J. Estimating the causal effect of compliance on binary outcome in randomized controlled trials. Statistics in Medicine 1998; 17; 341-55.
37. Albert JM and Demets DL. On a model-based approach to estimating efficacy in clinical trials. Statistics in Medicine 1994; 13: 2323-35.
38. Hirano K, Imbens GW, Rubin DB, Zhou X. Assessing the effect of an influenza vaccine in an encouragement design. Biostatistics 2000; 1: 69-88.
39. Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 2003; 59: 531-41.
40. Baker SG, Kramer BS, Prorok PC. Comparing cancer mortality rates before-and-after a change in availability of screening in different regions: Extension of the paired availability design. BMC Medical Research Methodology 2004; 4: 12.
41. Frangakis CE, Rubin DB, Zhou X. Clustered encouragement designs with individual noncompliance: Bayesian inference with randomization, and application to advance directive forms. Biostatistics 2002; 3: 147-64.
42. McIntosh MW. Instrumental variables when evaluating screening trials: estimating the benefit of detecting cancer by screening. Statistics in Medicine 1999; 18: 2775-94.
43. Sato T. A method for the analysis of repeated binary outcomes in randomized clinical trials with non-compliance. Statistics in Medicine 2001; 20: 2761-74.
44. Robins JM. Correction for non-compliance in equivalence trials. Statistics in Medicine 1998; 17: 269-302.
45. Nagelkerke N, Fidler V, Bensen R, Borgdorff M. Estimating treatment effects in randomized clinical trials in the presence of non-compliance. Statistics in Medicine 2000; 19: 1849-64.
46. Ten Have TR, Joffe M, Cary M. Causal logistic models for non-compliance under randomized treatment with univariate binary response. Statistics in Medicine 2003; 22: 1255-83.
47. Frangakis C, Baker SG. Compliance adjusted double-sampling designs for comparative research: estimation and optimal planning. Biometrics 2001; 57: 899-908.